Growing evidence suggests that aberrant epigenetic regulation of gene function is strongly
related to the genesis of cancer. Unlike genetic mutations, the ability to reprogram the …

Simple Summary Beyond mutations, epigenetic changes have been described as drivers for
cancer as well. While leaving the overall DNA structure intact, they can be responsible for …

Glioblastoma (GBM) is a highly malignant brain tumor characterized by a heterogeneous
population of genetically unstable and highly infiltrative cells that are resistant to …

Glioblastoma is the most common primary malignant brain tumor that is usually considered
fatal even with treatment. This is often a result for tumor to develop resistance. Regarding the …

Background Glioblastoma is associated with poor prognosis and high mortality. Although the
use of first-line temozolomide can reduce tumor growth, therapy-induced stress drives stem …

Simple Summary Tumor heterogeneity promotes the development of drug resistance in
cancer. HDAC inhibitors modulate several processes that contribute to intra-tumoral …

Acquisition of temozolomide (TMZ) resistance is a major factor leading to the failure of
glioblastoma (GBM) treatment. The exact mechanism by which GBM evades TMZ toxicity is …

Glioblastoma multiforme is the most aggressive type of primary brain tumor associated with
few therapeutic opportunities and poor prognosis. In this study, we evaluated the efficacy of …

Background Glioblastoma (GBM) is the most aggressive and lethal brain tumor. Although the
histone deacetylase (HDAC)/transcription factor axis promotes growth in GBM, whether …

Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain
tumor in adults, with a poor median survival of approximately 15 months after diagnosis …